FDA approves Roche's Tarceva for lung cancer maintenance use
This article was originally published in Scrip
Executive Summary
The US FDA has gone ahead and extended the approval of Roche/OSI Pharmaceuticals' EGFR-targeted drug Tarceva (erlotinib) for the maintenance treatment of advanced non-small cell lung cancer (NSCLC), despite a negative vote by its oncologic drugs advisory panel (ODAC) panel in December.